Pfizer’s candidate treatment for patients diagnosed with active ankylosing spondylitis (AS) was approved by the U.S. Food and Drug Administration under a supplemental New Drug Application.
Pfizer Inc. said on April 7 the U.S. Food and Drug Administration extended the review of the company’s experimental atopic dermatitis drug by three months, the latest regulatory setback for a class of treatments known as JAK inhibitors.
The FDA approved Eli Lilly and Co.’s Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active ankylosing spondylitis, also known as radiographic axial spondyloarthritis.